Angioplasty
Also known as: Balloon angioplasty, Coronary angioplasty, Percutaneous coronary intervention (PCI)
Methodology & AI Transparency ⓘ
Angioplasty Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is angioplasty? Angioplasty is a procedure to improve blood flow in coronary arteries that have become narrow or blocked.
- 2 Real-world patient consensus: Clinical coding for Angioplasty uses ICD-10 I51.9 across Heart & Vascular specialty care.
- 3 Typical cash cost range: Workup highlights for Angioplasty (I51.9): hemodynamic risk profiling [Angioplasty I51.9].
- 4 Top reported side effects / signs: Objective lab/clinical target for Angioplasty: Left Ventricular Ejection in Angioplasty (I51.9: Fraction (LVEF)) (55% – 70% (I51.9)) and NT-proBNP [Angioplasty I51.9].
Ask our AI Specialists anything about Angioplasty
What Is Angioplasty?
What is angioplasty? Angioplasty is a procedure to improve blood flow in coronary arteries that have become narrow or blocked. Your coronary arteries supply oxygen-rich blood to your heart. If you have coronary artery disease , a sticky material called plaque builds up in your coronary arteries. Plaque is made of cholesterol , calcium, and other substances in your blood. Over time, it can narrow your arteries or fully block them. When this happens, some parts of your heart don't get enough blood. Angioplasty widens the blocked part of your artery so more blood can get through. It is also called percutaneous coronary intervention (PCI).
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in heart & vascular, Angioplasty (I51.9) involves fibrotic extracellular matrix in Angioplasty (I51.9: deposition). Cross-referenced with NIH MeSH (Angioplasty), progression correlates with shifts in Left Ventricular Ejection in Angioplasty (I51.9: Fraction (LVEF)) (55% – 70% (I51.9)).
Common Symptoms & Clinical Signs
- • Limit damage to the heart during or right after a heart attack . In this case, angioplasty is an emergency treatment
- • Make a small opening in that area to insert a thin tube (a catheter) into a blood vessel
- • Presentation of Angioplasty (I51.9): unexplained lower-extremity ankle in Angioplasty (I51.9: edema or rapid)
- • Secondary Angioplasty clinical sign: reduced exercise tolerance in Angioplasty (I51.9: and premature cardiovascular)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Angioplasty Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I51.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Heart & Cardiovascular Disease | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Left Ventricular Ejection in Angioplasty (I51.9: Fraction (LVEF)) | 55% – 70% (I51.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: NT-proBNP [Angioplasty I51.9] | < 100 pg/mL (I51.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: High-Sensitivity Troponin I [Angioplasty I51.9] | < 14 ng/L (I51.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Angioplasty
Treatment selection for Angioplasty depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Angioplasty)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Sirolimus-Coated Balloon Angioplasty for Infrainguinal Artery New England Journal of Medicine, Volume 395, Issue 17 , Page 1765-1767, October 29, 2026. New England Journal of Medicine • 2026-10-28 • Peer-Reviewed Journal (Clinical Trials) | Multi-cohort | 96/100 | PMID NEJM-3472488654 ↗ |
| New Insights on Rosuvastatin for Reduction of Myocardial Damage during Coronary Angioplasty - the: What a 1,080-Participant Study Found Endpoints of the EPC-substudies are the impact of tested regimens on 1) early (24-h) and 3-month EPC levels and functional activity; 2) stent strut re-endothelialization and neointimal hyperplasia; 3) 1-year MACE. Cardiovascular drugs and therapy • 2016-10-15 • Randomized Controlled Trial | N = 1,080 | 96/100 | PMID 27358173 ↗ |
| New Insights on Design of the heart failure endpoint evaluation of AII-antagonist losartan: What a 3,834-Participant Study Found The results of HEAAL should facilitate selection of an optimal dosing regimen for losartan in patients with symptomatic heart failure who are intolerant of ACE-inhibitors. European journal of heart failure • 2008-09-15 • Randomized Controlled Trial | N = 3,834 | 90/100 | PMID 18768350 ↗ |
| Can This Approach Help? Inside the Latest Research on Amustaline/glutathione pathogen-reduced red cell hemoglobin utilization in PR-RBCs contained 5.2% less Hb (mean [SD] Test 58.1 [6.5] g; Control 61.5 [6.8] g Hb, p < .001) due to manufacturing volume losses. Transfusion • 2026-01-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 41317318 ↗ |
| Can This Approach Help? Inside the Latest Research on Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of We reported that both statins similarly decreased the endocan levels, whereas rosuvastatin seems to have more prominent effects on the reduction of the chemerin and galectin-3 levels in patients with AMI. Anatolian journal of cardiology • 2019-11-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 31674929 ↗ |
Angioplasty Patient Community & “People Like Me” Threads
Filter Angioplasty community threads and patient logs by age, biological sex, dosage, and treatment duration.
Tracking Left Ventricular Ejection in Angioplasty (I51.9: Fraction (LVEF)) every 12 weeks for Angioplasty: what lab cadence worked best?
FDA/PubMed Clinical Context Note: Clinical guidelines across Heart & Cardiovascular Disease (Angioplasty, ICD-10-CM I51.9) generally pair 8-to-12-week repeat biomarker verification (Left Ventricular Ejection in Angioplasty (I51.9: Fraction (LVEF)): 55% – 70% (I51.9)) with symptom review so steady-state physiological response is captured accurately.
After being diagnosed with Angioplasty (ICD-10 I51.9), my clinician and I set a goal around Left Ventricular Ejection in Angioplasty (I51.9: Fraction (LVEF)) (55% – 70% (I51.9)) before escalating medication doses. For others managing heart & vascular markers, did quarterly bloodwork catch changes early enough without over-testing?
12-week intervals worked really well for tracking Left Ventricular Ejection in Angioplasty (I51.9: Fraction (LVEF)). Using the same morning fasting draw window each quarter eliminated day-to-day noise so my doctor could adjust cleanly.
Ordering Left Ventricular Ejection in Angioplasty (I51.9: Fraction (LVEF)) alongside standard preventive labs prior to my follow-up visit saved an extra co-pay and kept our appointment focused on actual trend lines.